(Q35904814)

11 August 2017

1 reference

title

Moxifloxacin: a review of its use in the management of bacterial infections (English)

1 reference

11 August 2017

1 reference

2

Lesley J Scott

1 reference

11 August 2017

1

Gillian M Keating

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

64

1 reference

11 August 2017

issue

20

1 reference

11 August 2017

page(s)

2347-2377

1 reference

Gatifloxacin, Gemifloxacin, and Moxifloxacin: The Role of 3 Newer Fluoroquinolones

11 August 2017

cites work

1 reference

12 December 2020

Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions

1 reference

12 December 2020

Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers

1 reference

12 December 2020

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

1 reference

12 December 2020

In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections

1 reference

12 December 2020

Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model

1 reference

12 December 2020

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

1 reference

12 December 2020

Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect

1 reference

12 December 2020

Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates

1 reference

12 December 2020

Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers

1 reference

12 December 2020

Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers

1 reference

12 December 2020

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

1 reference

12 December 2020

Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing

1 reference

12 December 2020

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies

1 reference

12 December 2020

Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone

1 reference

12 December 2020

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

1 reference

12 December 2020

Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state

1 reference

12 December 2020

Antibiotic therapy in acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999.

1 reference

12 December 2020

Pharmacodynamics of fluoroquinolones

1 reference

12 December 2020

Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers

1 reference

12 December 2020

Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae.

1 reference

12 December 2020

Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana

1 reference

12 December 2020

Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model

1 reference

12 December 2020

Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci

1 reference

12 December 2020

Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

1 reference

12 December 2020

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus

1 reference

12 December 2020

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

1 reference

12 December 2020

Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone

1 reference

12 December 2020

Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.

1 reference

12 December 2020

National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents

1 reference

12 December 2020

Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur).

1 reference

12 December 2020

The influence of age and gender on the pharmacokinetics of moxifloxacin

1 reference

12 December 2020

In vitro antibacterial activity and pharmacodynamics of new quinolones

1 reference

12 December 2020

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

12 December 2020

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia

1 reference

12 December 2020

Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group

1 reference

12 December 2020

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae

1 reference

12 December 2020

Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci

1 reference

12 December 2020

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

12 December 2020

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States

1 reference

12 December 2020

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

12 December 2020

Acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Photochemical mutagenicity of phototoxic and photochemically carcinogenic fluoroquinolones in comparison with the photostable moxifloxacin

1 reference

12 December 2020

Activity of and resistance to moxifloxacin in Staphylococcus aureus

1 reference

12 December 2020

Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

1 reference

12 December 2020

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

1 reference

12 December 2020

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

1 reference

12 December 2020

An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.

1 reference

12 December 2020

Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration

1 reference

12 December 2020

In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity

1 reference

12 December 2020

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

1 reference

12 December 2020

Canadian guidelines for the management of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Profile of moxifloxacin drug interactions

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae

1 reference

12 December 2020

Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom

1 reference

12 December 2020

Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans

1 reference

12 December 2020

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

12 December 2020

In vitro development of resistance to three quinolones in Streptococcus pneumoniae

1 reference

12 December 2020

Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk

1 reference

12 December 2020

Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint

1 reference

12 December 2020

Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans

1 reference

12 December 2020

Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae

1 reference

12 December 2020

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone

1 reference

12 December 2020

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

1 reference

12 December 2020

Fluoroquinolone adverse effects and drug interactions

1 reference

12 December 2020

Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis.

1 reference

12 December 2020

The role of fluoroquinolones in skin and skin structure infections

1 reference

12 December 2020

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

1 reference

12 December 2020

Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria

1 reference

12 December 2020

Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum

1 reference

12 December 2020

Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales

1 reference

12 December 2020

Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila

1 reference

12 December 2020

Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada

1 reference

12 December 2020

Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline

1 reference

12 December 2020

Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration

1 reference

12 December 2020

Fluoroquinolones in the elderly: safety considerations

1 reference

12 December 2020

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

1 reference

12 December 2020

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms

1 reference

12 December 2020

Maintaining fluoroquinolone class efficacy: review of influencing factors

1 reference

12 December 2020

Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens

1 reference

12 December 2020

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).

1 reference

12 December 2020

Mechanism of action of and resistance to quinolones

1 reference

12 December 2020

Pharmacokinetics and metabolism of moxifloxacin

1 reference

12 December 2020

Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams

1 reference

12 December 2020

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.

1 reference

12 December 2020

Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction

1 reference

12 December 2020

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Improving care for patients with respiratory tract infections.

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae

1 reference

12 December 2020

Clinical perspectives on new antimicrobials: focus on fluoroquinolones

1 reference

12 December 2020

A critical review of the fluoroquinolones: focus on respiratory infections

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

12 December 2020

Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces

1 reference

12 December 2020

Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers

1 reference

12 December 2020

Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin

1 reference

12 December 2020

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model

1 reference

12 December 2020

Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects

1 reference

12 December 2020

Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults

1 reference

12 December 2020

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies

1 reference

12 December 2020

New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?

1 reference

12 December 2020

Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections

1 reference

12 December 2020

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

1 reference

12 December 2020

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.

1 reference

12 December 2020

Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis

1 reference

12 December 2020

Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers

1 reference

12 December 2020

Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.

1 reference

12 December 2020

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

12 December 2020

Toxicity of quinolones

1 reference

12 December 2020

Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?

1 reference

12 December 2020

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

12 December 2020

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

1 reference

12 December 2020

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

12 December 2020

Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.

1 reference

12 December 2020

Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain

1 reference

12 December 2020

ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society

1 reference

12 December 2020

Penetration of moxifloxacin into peripheral compartments in humans.

1 reference

12 December 2020

Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia

1 reference

12 December 2020

In vitro development of resistance to newer fluoroquinolones in Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin

1 reference

12 December 2020

Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience

1 reference

12 December 2020

In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.

1 reference

12 December 2020

Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model

1 reference

12 December 2020

Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

1 reference

12 December 2020

The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens

1 reference

12 December 2020

A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group

1 reference

12 December 2020

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model

1 reference

12 December 2020

A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis

1 reference

12 December 2020

Antimicrobial treatment guidelines for acute bacterial rhinosinusitis

1 reference

12 December 2020

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

1 reference

12 December 2020

Bactericidal properties of moxifloxacin and post-antibiotic effect.

1 reference

12 December 2020

Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study

1 reference

12 December 2020

The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

12 December 2020

Moxifloxacin in uncomplicated skin and skin structure infections

1 reference

12 December 2020

Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model

1 reference

12 December 2020

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

12 December 2020

10.2165/00003495-200464200-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1017552627

0 references

1 reference